This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Subsidiary has received one inspectional observation in Form 483
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Delivers robust earnings performance, successfully navigating a dynamic environment
This approval authorizes the company to export Ibuprofen to the Chinese markets
The inspection concluded with 6 observations and none of them were related to Data Integrity
Subscribe To Our Newsletter & Stay Updated
